MedTrace Logo

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

NCT04938583 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-04-06

No results posted yet for this study

Summary

This is a single arm phase 1b/2 evaluation of the combination of oregovomab, and bevacizumab, paclitaxel carboplatin in adult subjects with CA125-associated, advanced recurrent epithelial ovarian, fallopian tube or peritoneal carcinoma (FIGO Stage III/IV) with BRCA-wild type, previously treated with 1 prior lines of therapy, and with platinum free intervals of \>6 months since last platinum-based treatment.

Conditions

  • Ovarian Cancer by FIGO Stage
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage IV

Interventions

BIOLOGICAL

Oregovomab

Oregovomab will be administered on day1 cycle 1, 3, 5, and 9. A minimum of 3 patients will be enrolled into each cohort (2 mg or 1 mg). 2 mg (starting dose), dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

DRUG

Bevacizumab

15mg/Kg Day 1 (every 21 days) until progression

DRUG

Paclitaxel

175 mg/m\^2, Day 1 x 6 cycles (every 21 days)

DRUG

Carboplatin

AUC 5 IV Day 1 x 6 cycles (every 21 days)

Sponsors & Collaborators

  • Korean Cancer Study Group

    collaborator OTHER

  • CanariaBio Inc.

    lead INDUSTRY

Principal Investigators

  • Dr Jung KH, MD · Asan Medical Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2025-10-30
Completion
2026-08-31
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938583 on ClinicalTrials.gov